For sponsors and CROs
Your studies are already listed. The question is who sees them.
Every recruiting NCT in the United States has a page here whether or not we have ever spoken. What is buyable is attention: putting a specific study in front of patients searching in the metros where your enrollment curve is behind.
Applications from hipa.ai reached these sponsors' trials:
- Eli Lilly
- Novo Nordisk
- Pfizer
- AbbVie
- Amgen
- Kailera
- Stryker
- Bristol-Myers Squibb
- Merck
- Boston Scientific
Listed sponsors received at least one completed application to one of their studies in this window. Being listed does not imply a commercial relationship with Hipa.ai.
Buy the metros, not the impressions.
Enrollment is never behind everywhere at once. It is behind at four sites in three cities, and that is the unit worth buying.
Geo-targeted placement
A study is surfaced to patients searching in the metros you name, on the city, condition and drug pages that already rank there. Targeting is by location, condition and study — not a display network.
Google for Jobs postings
For paid studies, per-city postings put the trial in a surface most recruitment vendors ignore entirely — people searching for paid work in their city, which is a large and under-served source of healthy volunteers.
Routing to the right site
Applicants are routed to the nearest participating location by distance from their own postcode, and handed to that site’s own contact — not pooled into a call centre that phones back in three days.
A screened person, and the answers behind the verdict.
“Qualified” is a word this industry uses loosely, so here is exactly what it means on this platform: the applicant answered the protocol’s own inclusion and exclusion questions, their email and phone were verified, their location was checked, and the answers were read against the criteria before the referral went anywhere.
The site receives the verdict and the underlying answers, so their own screening call starts from something rather than from scratch. What we cannot promise, and will not, is that a screened applicant randomises — that depends on your protocol and their site.
Applications, by study and by site.
You see what was delivered and where it went. We do not charge for impressions.
That last line is the one worth watching. Across the whole platform, the large majority of referrals we hand to sites have never been opened — which is usually a site-capacity problem rather than a lead-quality one, and it is far cheaper to fix than buying more traffic.
Tell us which cities are behind.
Bring a study and the metros where enrollment is short. We will tell you what we can already see there.